Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SOD1 | P00441 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662035 | 0.81 | MAOB (0.49) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3636719 | 0.77 | MAOB (0.55) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL23302996 | 0.77 | IDO1 (0.44) | MAOBALDH1A1 | |
| SCHEMBL5334810 | 0.76 | LMNA (0.40) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL754086 | 0.75 | TRPA1 (0.38) | ALDH1A1HTT | |
| SCHEMBL19384427 | 0.74 | MAOB (0.51) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL31173236 | 0.74 | MAOB (0.51) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL27075523 | 0.74 | MAOB (0.51) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL19384488 | 0.73 | MAOB (0.50) | MAOBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL16256459 | 0.73 | MAOB (0.50) | MAOBKDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054724-A1 | BIFUNCTIONAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021086785-A1 | BIFUNCTIONAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| US-6890959-B2 | Aminomethyl-phenyl-cyclohexanone derivatives | GRUENENTHAL GMBH (DE) | 2005-05-10 | — | — | US | disclosed |
| EP-1246791-B1 | AMINOMETHYL-PHENYL-CYCLOHEXANONE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-20030096811-A1 | Aminomethyl-phenyl-cyclohexanone derivatives | GRUENENTHAL GMBH (DE) | 2003-05-22 | — | — | US | disclosed |
| EP-0922703-B1 | Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds | GRUENENTHAL GMBH (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1246791-A2 | AMINOMETHYL-PHENYL-CYCLOHEXANONE DERIVATIVES | Grünenthal GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| EP-0864559-B1 | Substituted amino compounds and their use as analgesic active substances | GRUENENTHAL GMBH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001049651-A2 | AMINOMETHYL-PHENYL-CYCLOHEXANONE DERIVATIVES | Grünenthal GmbH (DE) | 2001-07-12 | — | — | WO | disclosed |
| US-6022895-A | Substituted amino compounds and their use as substances having an analgesic effect | GRUENENTHAL GMBH (DE) | 2000-02-08 | — | — | US | disclosed |
| US-6013809-A | ANALGESICS | GRUENENTHAL GMBH (DE) | 2000-01-11 | — | — | US | disclosed |
| EP-0922703-A1 | Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds | Grünenthal GmbH (DE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0864559-A1 | Substituted amino compounds and their use as analgesic active substances | Grünenthal GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096811-A1 | Aminomethyl-phenyl-cyclohexanone derivatives | CYP2J2, CYP2E1, CYP2D6 | MAOB 263/4885KDM4E 833/4885ALDH1A1 78/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | MAOB 3298/4885KDM4E 3571/4885ALDH1A1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.